ProfileGDS5678 / 1423619_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 9% 9% 10% 10% 29% 8% 10% 73% 64% 11% 9% 10% 9% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.243539
GSM967853U87-EV human glioblastoma xenograft - Control 22.228389
GSM967854U87-EV human glioblastoma xenograft - Control 32.2373410
GSM967855U87-EV human glioblastoma xenograft - Control 42.2054810
GSM967856U87-EV human glioblastoma xenograft - Control 52.6105529
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.250198
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.2767110
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.639973
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8502564
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.2676511
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.19439
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.2290210
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.228279
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.216789